Ypsomed goes direct in India
This article was originally published in Clinica
Swiss pen injector manufacturer Ypsomed is opening a subsidiary in India to capitalise on the rapidly rising number of diabetics in the country. According to the Burgdorf company, the Indian insulin market is expected to grow from SwFr88m ($78.7m) in 2005 to SwFr121m in 2010. While 85% of insulin is currently injected with normal syringes, sales of pen injector systems in India is growing at 35% each year, said Ypsomed. The company already has a presence in Asia, with distributors in Singapore, Malaysia and Iran.
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.